Early molecular responses of bone to obstructive nephropathy induced by unilateral ureteral obstruction in mice

Nephrology

Volumn 17, Issue 8, 2012, Pages 767-773

  Gu, Sa Sa ^a   Zhang, Yan ^a   Wu, Shu Yan ^a   Diao, Teng Yue ^a   Gebru, Yoseph Asmelash ^a   Deng, Hong Wen ^a,b  

^a UNIVERSITY OF SHANGHAI FOR SCIENCE AND TECHNOLOGY   (China)

^b TULANE UNIVERSITY   (United States)

Author keywords

angiotensin II; bone; renal osteodystrophy; renin angiotensin system; unilateral ureteral obstruction

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CALCIUM; CATHEPSIN K; COLLAGEN; EOSIN; HEMATOXYLIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TARTARIC ACID; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BONE INJURY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARTILAGE CELL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; MALE; MOUSE; NONHUMAN; OSTEOID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; STAINING; TIBIA; UPREGULATION; URETER OBSTRUCTION; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; BONE REMODELING; CALCIUM; CHONDROCYTES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED ICR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ANGIOTENSIN, TYPE 2; RENAL OSTEODYSTROPHY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIBIA; TIME FACTORS; URETERAL OBSTRUCTION;

EID: 84868140994     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01656.x     Document Type: Article

References (29)

1. Al Badr W, Martin KJ,. Role of bone biopsy in renal osteodystrophy. Saudi J. Kidney Dis. Transpl. 2009; 20: 12-19.
2. Mesquita M, Wittersheim E, Demulder A, Dratwa M, Berqmann P,. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients. Adv. Perit. Dial. 2005; 21: 181-4.
3. Moe SM, Drüeke T,. Improving global outcomes in mineral and bone disorders. Clin. J. Am. Soc. Nephrol. 2008; 3: S127-S130.
4. Tomayko EJ, Chung HR, Wilund KR,. Soy protein diet and exercise training increase relative bone volume and enhance bone microarchitecture in a mouse model of uremia. J. Bone Miner. Metab. 2011; 29: 682-90.
5. Souqiyyeh MZ, Shaheen FA,. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Saudi J. Kidney Dis. Transpl. 2010; 21: 93-101.
6. Damment S, Secker R, Shen V, Lorenzo V, Rodriguez M,. Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Nephrol. Dial. Transplant. 2011; 26: 1803-12.
7. Asaba Y, Ito M, Fumoto T, et al,. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J. Bone Miner. Res. 2009; 24: 241-50.
8. Izu Y, Mizoguchi F, Kawamata A, et al,. Angiotensin II type 2 receptor blockade increases bone mass. J. Biol. Chem. 2009; 284: 4857-64.
9. Shimizu H, Nakagami H, Osako MK, et al,. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008; 22: 2465-75. (Pubitemid 351948664)
10. Hiruma Y, Inoue A, Hirose S, Hagiwara H,. Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem. Biophys. Res. Commun. 1997; 230: 176-8. (Pubitemid 27210267)
11. Shimizu H, Nakagami H, Osako MK, et al,. Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens. Res. 2009; 32: 786-90.
12. García-Testal A, Monzõ A, Rabanaque G, González A, Romeu A,. Evolution of the bone mass of hypertense menopausal women in treatment with fosinopril. Med. Clin. (Barc). 2006; 127: 692-4. (Pubitemid 46050998)
13. Lynn H, Kwok T, Wong SY, Woo J, Leung PC,. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 2006; 38: 584-8.
14. Schinke T, Karsenty G,. Transcriptional control of osteoblast differentiation and function. In:, Bilezikian JP, Raisz LG, Rodan GA, (eds). The Principles of Bone Biology, 2nd edn. San Diego, CA: Academic Press, 2002; 83-91.
15. Yamamoto Y, Udagawa N, Matsuura S, et al,. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. Endocrinology 2006; 147: 3366-74. (Pubitemid 43901128)
16. Fujisaki K, Tanabe N, Suzuki N, et al,. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci. 2007; 80: 1311-18.
17. Riihonen R, Supuran CT, Parkkila S, Pastorekova S, Vaananen HK, Laitala-Leinonen T,. Membrane-bound carbonic anhydrases in osteoclasts. Bone 2007; 40: 1021-31. (Pubitemid 46386547)
18. 2+. Exp. Cell Res. 1998; 242: 128-37. (Pubitemid 28366528)
19. Margolis DS, Szivek JA, Lai LW, Lien YH,. Phenotypic characteristics of bone in carbonic anhydrase II-deficient mice. Calcif. Tissue Int. 2008; 82: 66-76.
20. Tan X, Li Y, Liu Y,. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 2006; 17: 3382-93. (Pubitemid 44865281)
21. Zhang Y, Kong J, Chang A, Deb DK, Li YC,. Vitamin D receptor attenuates renal fibrosis in obstructive nephropathy by suppressing the renin-angiotensin system. J. Am. Soc. Nephrol. 2010; 21: 966-73.
22. Zhang Y, Dong XL, Leung PC, Wong MS,. Differential mRNA expression profiles in proximal tibia of aged rats in response to ovariectomy and low Ca diet. Bone 2009; 44: 46-52.
23. Zhang Y, Wu SY, Gu SS, Lv FK,. Changes of renal vitamin D metabolic enzyme expression and calcium transporter abundance in obstructive nephropathy. Nephrology 2011; 16: 710-14.
24. Oka K, Oka S, Hosokawa R, et al,. Chronic kidney disease: Acute manifestations and role of critical care nurses. Dev. Biol. 2008; 321: 303-9.
25. Van Der Kraan PM, Blaney Davidson EN, Blom A, Van Den Berg WB,. TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis: Modulation and integration of signaling pathways through receptor-Smads. Osteoarthritis Cartilage 2009; 17: 1539-45.
26. Siomou E, Challa A, Printza N, et al,. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr. Nephrol. 2011; 26: 1105-14.
27. Avbersek-Luznik I, Balon BP, Rus I, Marc J,. Increased bone resorption in HD patients: Is it caused by elevated RANKL synthesis? Nephrol. Dial. Transplant. 2005; 20: 566-70. (Pubitemid 40378426)
28. Kaneko K, Ito M, Fumoto T, et al,. Physiological function of the angiotensin AT1a receptor in bone remodeling. J. Bone Miner. Res. 2011; 26: 2959-66.
29. Bandow K, Nishikawa Y, Ohnishi T, et al,. Low-intensity pulsed ultrasound (LIPUS) induces RANKL, MCP-1, and MIP-1beta expression in osteoblasts through the angiotensin II type 1 receptor. J. Cell. Physiol. 2007; 211: 392-8. (Pubitemid 46580093)